Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06125327 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026 Completion date: Dec 31, 2025 to Dec 31, 2027 · Secondary endpoints: details revised at 1 of 2 entries · Study description shortened, about 172 wordsv2 Show 3 more changesShow less
    • Completion date: Dec 31, 2025 to Dec 31, 2027
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description shortened, about 172 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.
Trial Details
NCT Number NCT06125327
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov